Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

US Patent 10787521 · Granted Sep 29, 2020

Estimated economic value: $80,950,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD137 binding molecules and uses thereof2025
CD137 binding molecules and uses thereof2025
Organoids for drug screening and personalized medicine2025
Bispecific molecules comprising an HIV-1 envelope targeting arm2024
CD3-binding molecules capable of binding to human and non-human CD32024
CD3-binding molecules capable of binding to human and non-human CD32024
HER2/neu-specific antibodies and methods of using same2024
HER2/neu-specific antibodies and methods of using same2024
HER2/neu-specific antibodies and methods of using same2024
Bispecific binding molecules that are capable of binding CD137 and tumor antigen2024
Bispecific binding molecules that are capable of binding CD137 and tumor antigen2024
Bispecific binding molecules that are capable of binding CD137 and tumor antigen2024